Article
EML4-ALK G1202R and EML4-ALK L1196M mutations induce crizotinib resistance in non-small cell lung cancer cells through activating epithelial-mesenchymal transition mediated by MDM2/MEK/ERK signal axis.
Cell biology international - 1 Jan 2025
Yang Yuying, Yang Huan, Gao Yunhui, Yang Qian, Zhu Xinya, Miao Qianying, Xu Xiaobo, Li Zengqiang, Zuo Daiying
Abstract excerpt
Crizotinib, as the first-generation of anaplastic lymphoma kinase (ALK) inhibitor, effectively improves the survival time of ALK-positive non-small cell lung cancer (NSCLC) patients. However, its efficacy is severely limited by drug resistance caused by secondary mutations. G1202R and L1196M are classical mutation sites located in ALK kinase domain. They may hinder the binding of ALK inhibitors to the target...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.